Epitomee Medical Ltd (EPIT) - Total Assets
Based on the latest financial reports, Epitomee Medical Ltd (EPIT) holds total assets worth ILA37.04 Million ILA (≈ $99.31K USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Epitomee Medical Ltd (EPIT) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Epitomee Medical Ltd - Total Assets Trend (2018–2024)
This chart illustrates how Epitomee Medical Ltd's total assets have evolved over time, based on quarterly financial data. See EPIT net asset value for net asset value and shareholders' equity analysis.
Epitomee Medical Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Epitomee Medical Ltd's total assets of ILA37.04 Million consist of 55.9% current assets and 44.1% non-current assets.
| Asset Category | Amount (ILA) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 41.2% |
| Accounts Receivable | ILA213.00K | 0.5% |
| Inventory | ILA16.00K | 0.0% |
| Property, Plant & Equipment | ILA0.00 | 0.0% |
| Intangible Assets | ILA0.00 | 0.0% |
| Goodwill | ILA0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Epitomee Medical Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see EPIT market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Epitomee Medical Ltd's current assets represent 55.9% of total assets in 2024, a decrease from 74.7% in 2018.
- Cash Position: Cash and equivalents constituted 41.2% of total assets in 2024, down from 72.1% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 0.5% of total assets.
Epitomee Medical Ltd Competitors by Total Assets
Key competitors of Epitomee Medical Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
APT Medical Inc
SHG:688617
|
China | CN¥3.43 Billion |
|
Medacta Group SA
SW:MOVE
|
Switzerland | CHF860.76 Million |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.52 Billion |
|
Shanghai MicroPort EV MedTech Co. Ltd. A
SHG:688351
|
China | CN¥2.00 Billion |
|
HOB Biotech Group Corp Ltd
SHG:688656
|
China | CN¥912.83 Million |
|
Shanghai General Healthy Information and Technology Co. Ltd.
SHG:605186
|
China | CN¥1.59 Billion |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607
|
China | CN¥988.48 Million |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.02 Billion |
Epitomee Medical Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.72 | 15.87 | 26.86 |
| Quick Ratio | 7.65 | 15.87 | 26.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ILA16.39 Million | ILA27.69 Million | ILA19.92 Million |
Epitomee Medical Ltd - Advanced Valuation Insights
This section examines the relationship between Epitomee Medical Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.19 |
| Latest Market Cap to Assets Ratio | 0.65 |
| Asset Growth Rate (YoY) | -0.1% |
| Total Assets | ILA40.21 Million |
| Market Capitalization | $26.17 Million USD |
Valuation Analysis
Below Book Valuation: The market values Epitomee Medical Ltd's assets below their book value (0.65x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Epitomee Medical Ltd's assets decreased by 0.1% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Epitomee Medical Ltd (2018–2024)
The table below shows the annual total assets of Epitomee Medical Ltd from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ILA40.21 Million ≈ $107.81K |
-0.13% |
| 2023-12-31 | ILA40.27 Million ≈ $107.95K |
-27.06% |
| 2022-12-31 | ILA55.20 Million ≈ $147.99K |
-16.39% |
| 2021-12-31 | ILA66.02 Million ≈ $177.01K |
+209.65% |
| 2020-12-31 | ILA21.32 Million ≈ $57.16K |
+177.31% |
| 2019-12-31 | ILA7.69 Million ≈ $20.61K |
+209.17% |
| 2018-12-31 | ILA2.49 Million ≈ $6.67K |
-- |
About Epitomee Medical Ltd
Epitomee Medical Ltd, a biomedical company, develops and commercializes ingestible therapeutic devices worldwide. It offers capsules, which are polymer-based scaffold for controlled delivery of therapies along the GI tract for weight management and biologics delivery. The company was incorporated in 2005 and is based in Caesarea, Israel.